Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.8 USD | -0.11% | +6.93% | +140.44% |
May. 29 | Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target | MT |
May. 13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 632M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -107M | EV / Sales 2024 * | - |
Net cash position 2024 * | 185M | Net cash position 2025 * | 100M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.83
x | P/E ratio 2025 * |
-6.23
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.33% |
Latest transcript on Mind Medicine (MindMed) Inc.
1 day | -0.11% | ||
1 week | +6.93% | ||
1 month | -6.68% | ||
3 months | +41.25% | ||
6 months | +150.00% | ||
Current year | +140.44% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Barrow
CEO | Chief Executive Officer | 35 | 21-01-13 |
Miri Wernli
PSD | President | 71 | 20-02-27 |
Daniel Karlin
CTO | Chief Tech/Sci/R&D Officer | 44 | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andreas Krebs
BRD | Director/Board Member | 65 | 21-09-28 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 22-08-10 |
David Gryska
BRD | Director/Board Member | 68 | 23-06-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 8.8 | -0.11% | 2,702,745 |
24-05-30 | 8.81 | -1.12% | 998,376 |
24-05-29 | 8.91 | +6.64% | 1,787,761 |
24-05-28 | 8.355 | +1.52% | 943,128 |
24-05-24 | 8.23 | +3.52% | 974,867 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+140.44% | 632M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- MNMD Stock